SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria

Biopharmaceutics and Drug Disposition

Volumn 35, Issue 7, 2014, Pages 391-404

  Chino, Yukihiro ^a,b   Samukawa, Yoshishige ^b   Sakai, Soichi ^b   Nakai, Yasuhiro ^b   Yamaguchi, Jun Ichi ^b   Nakanishi, Takeo ^a   Tamai, Ikumi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

GLUT9; SGLT2 inhibitor; sodium glucose cotransporter; uric acid; urinary glucose excretion

Indexed keywords

CARBON 14; FACILITATIVE GLUCOSE TRANSPORTER 9 ISOFORM 2; GLUCOSE; GLUCOSE TRANSPORTER; LUSEOGLIFLOZIN; PLACEBO; UNCLASSIFIED DRUG; URIC ACID; 1,5-ANHYDRO-1-(5-(4-ETHOXYBENZYL)-2-METHOXY-4-METHYLPHENYL)-1-THIOGLUCITOL; BIOLOGICAL MARKER; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2; SORBITOL;

ADULT; ANIMAL CELL; APICAL MEMBRANE; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TRANSPORT; FEMALE; GLUCOSURIA; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; KIDNEY TUBULE; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE CELL; MALE; NONHUMAN; NORMAL HUMAN; OOCYTE; PROTEIN EXPRESSION; SINGLE DRUG DOSE; URIC ACID BLOOD LEVEL; URINARY EXCRETION; XENOPUS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TRANSPORT AT THE CELLULAR LEVEL; XENOPUS LAEVIS; YOUNG ADULT;

ADULT; ANIMALS; BIOLOGICAL MARKERS; BIOLOGICAL TRANSPORT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOSE; GLYCOSURIA; HUMANS; KIDNEY TUBULES; MALE; SODIUM-GLUCOSE TRANSPORTER 2; SORBITOL; URIC ACID; XENOPUS LAEVIS; YOUNG ADULT;

EID: 84908555003     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1909     Document Type: Article

References (52)

1. +/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for d -glucose. J Clin Invest 1994; 93: 397-404. doi: 10.1172/jci116972.
2. +-coupled glucose transporters in adult and embryonic rat kidney. J Biol Chem 1995; 270: 29365-29371. doi: 10.1074/jbc.270.49.29365.
3. Nair S, Wilding JP,. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab 2010; 95: 34-42. doi: 10.1210/jc.2009-0473.
4. Bailey CJ,. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci 2011; 32: 63-71. doi: 10.1016/j.tips.2010.11.011.
5. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF,. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 2223-2233. 10.1016/s0140-6736(10)60407-2.
6. Cefalu WT, Leiter LA, Yoon KH, et al., Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013; 382: 941-950. 10.1016/s0140-6736(13)60683-2.
7. Wilding JP, Ferrannini E, Fonseca VA, et al., Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. Diabetes Obes Metab 2013; 15: 403-409. doi: 10.1111/dom.12038.
8. Ferrannini E, Seman L, Seewaldt-Becker E, et al., A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab 2013; 15: 721-728. doi: 10.1111/dom.12081.
9. Kakinuma H, Oi T, Hashimoto-Tsuchiya Y, et al., (1S)-1,5-Anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio- d -glucito l (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. J Med Chem 2010; 53: 3247-3261. doi: 10.1021/jm901893x.
10. Yamamoto K, Uchida S, Kitano K, et al., TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity. Br J Pharmacol 2011; 164: 181-191. doi: 10.1111/j.1476-5381.2011.01340.x.
11. Skeith MD, Healey LA, Cutler RE,. Effect of phloridzin on uric acid excretion in man. Am J Physiol 1970; 219: 1080-1082.
12. Campion EW, Glynn RJ, DeLabry LO,. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 1987; 82: 421-426.
13. Lin KC, Lin HY, Chou P,. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol 2000; 27: 1501-1505.
14. Iseki K, Oshiro S, Tozawa M, et al., Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res 2001; 24: 691-697. doi: 10.1291/hypres.24.691.
15. Chonchol M, Shlipak MG, Katz R, et al., Relationship of uric acid with progression of kidney disease. Am J Kidney Dis 2007; 50: 239-247. doi: 10.1053/j.ajkd.2007.05.013.
16. Ishizaka N, Ishizaka Y, Toda E, Nagai R, Yamakado M,. Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. Arterioscler Thromb Vasc Biol 2005; 25: 1038-1044. doi: 10.1161/01.atv.0000161274.87407.26.
17. Choi HK, Ford ES,. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 2007; 120: 442-447. doi: 10.1016/j.amjmed.2006.06.040.
18. Ward HJ,. Uric acid as an independent risk factor in the treatment of hypertension. Lancet 1998; 352: 670-671. 10.1016/s0140-6736(05)60816-1.
19. Shankar A, Klein R, Klein BE, Nieto FJ,. The association between serum uric acid level and long-term incidence of hypertension: population-based cohort study. J Hum Hypertens 2006; 20: 937-945. doi: 10.1038/sj.jhh.1002095.
20. Alderman MH, Cohen H, Madhavan S, Kivlighn S,. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999; 34: 144-150. doi: 10.1161/01.HYP.34.1.144.
21. Zoppini G, Targher G, Negri C, et al., Elevated serum uric acid concentrations independently predict cardiovascular mortality in type 2 diabetic patients. Diabetes Care 2009; 32: 1716-1720. doi: 10.2337/dc09-0625.
22. So A, Thorens B,. Uric acid transport and disease. J Clin Invest 2010; 120: 1791-1799. doi: 10.1172/jci42344.
23. Hosomi A, Nakanishi T, Fujita T, Tamai I,. Extra-renal elimination of uric acid via intestinal efflux transporter BCRP/ABCG2. PLoS One 2012; 7: e30456. doi: 10.1371/journal.pone.0030456.
24. Enomoto A, Kimura H, Chairoungdua A, et al., Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002; 417: 447-452. doi: 10.1038/nature742.
25. Kolz M, Johnson T, Sanna S, et al., Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet 2009; 5: e1000504. doi: 10.1371/journal.pgen.1000504.
26. Hagos Y, Stein D, Ugele B, Burckhardt G, Bahn A,. Human renal organic anion transporter 4 operates as an asymmetric urate transporter. J Am Soc Nephrol 2007; 18: 430-439. doi: 10.1681/asn.2006040415.
27. Bahn A, Hagos Y, Reuter S, et al., Identification of a new urate and high affinity nicotinate transporter, hOAT10 (SLC22A13). J Biol Chem 2008; 283: 16332-16341. doi: 10.1074/jbc.M800737200.
28. Li S, Sanna S, Maschio A, et al., The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts. PLoS Genet 2007; 3: e194. doi: 10.1371/journal.pgen.0030194.
29. Vitart V, Rudan I, Hayward C, et al., SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 2008; 40: 437-442. doi: 10.1038/ng.106.
30. Anzai N, Ichida K, Jutabha P, et al., Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J Biol Chem 2008; 283: 26834-26838. doi: 10.1074/jbc.C800156200.
31. Caulfield MJ, Munroe PB, O'Neill D, et al., SLC2A9 is a high-capacity urate transporter in humans. PLoS Med 2008; 5: e197. doi: 10.1371/journal.pmed.0050197.
32. Iwanaga T, Sato M, Maeda T, Ogihara T, Tamai I,. Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther 2007; 320: 211-217. doi: 10.1124/jpet.106.112755.
33. Facchini F, Chen YD, Hollenbeck CB, Reaven GM,. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991; 266: 3008-3011. doi: 10.1001/jama.1991.03470210076036.
34. Quinones Galvan A, Natali A, Baldi S, et al., Effect of insulin on uric acid excretion in humans. Am J Physiol 1995; 268: E1-E5.
35. Herman JB, Medalie JH, Goldbourt U,. Diabetes, prediabetes and uricaemia. Diabetologia 1976; 12: 47-52.
36. Herman JB, Goldbourt U,. Uric acid and diabetes: observations in a population study. Lancet 1982; 2: 240-243.
37. Gotfredsen A, McNair P, Christiansen C, Transbol I,. Renal hypouricaemia in insulin treated diabetes mellitus. Clin Chim Acta 1982; 120: 355-361.
38. Choi HK, Ford ES,. Haemoglobin A1c, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels-The Third National Health and Nutrition Examination Survey. Rheumatology (Oxford) 2008; 47: 713-717. doi: 10.1093/rheumatology/ken066.
39. Sasaki T, Seino Y, Fukatsu A, Sakai S, Samukawa Y,. Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: a randomized, single-blind, placebo-controlled trial. Adv Ther 2014; 31: 345-361. doi: 10.1007/s12325-014-0102-3.
40. Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I,. Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther 2004; 308: 438-445. doi: 10.1124/jpet.103.060194.
41. Iwanaga T, Kobayashi D, Hirayama M, Maeda T, Tamai I,. Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone. Drug Metab Dispos 2005; 33: 1791-1795. doi: 10.1124/dmd.105.006056.
42. Nakanishi T, Ohya K, Shimada S, Anzai N, Tamai I,. Functional cooperation of URAT1 (SLC22A12) and URATv1 (SLC2A9) in renal reabsorption of urate. Nephrol Dial Transplant 2013; 28: 603-611. doi: 10.1093/ndt/gfs574.
43. Lu Y, Nakanishi T, Tamai I,. Functional cooperation of SMCTs and URAT1 for renal reabsorption transport of urate. Drug Metab Pharmacokinet 2013; 28: 153-158. doi: 10.2133/dmpk.DMPK-12-RG-070.
44. Thangaraju M, Ananth S, Martin PM, et al., c/ebpdelta Null mouse as a model for the double knock-out of slc5a8 and slc5a12 in kidney. J Biol Chem 2006; 281: 26769-26773. doi: 10.1074/jbc.C600189200.
45. Benedict JD, Forsham PH, Stetten D Jr,. The metabolism of uric acid in the normal and gouty human studied with the aid of isotopic uric acid. J Biol Chem 1949; 181: 183-193.
46. Knight TF, Senekjian HO, Sansom S, Weinman EJ,. Effects of intraluminal d -glucose and probenecid on urate absorption in the rat proximal tubule. Am J Physiol 1979; 236: F526-529.
47. Yu L, Lv JC, Zhou XJ, et al., Abnormal expression and dysfunction of novel SGLT2 mutations identified in familial renal glucosuria patients. Hum Genet 2011; 129: 335-344. doi: 10.1007/s00439-010-0927-z.
48. Augustin R, Carayannopoulos MO, Dowd LO, et al., Identification and characterization of human glucose transporter-like protein-9 (GLUT9): alternative splicing alters trafficking. J Biol Chem 2004; 279: 16229-16236. doi: 10.1074/jbc.M312226200.
49. Witkowska K, Smith KM, Yao SY, et al., Human SLC2A9a and SLC2A9b isoforms mediate electrogenic transport of urate with different characteristics in the presence of hexoses. Am J Physiol Renal Physiol 2012; 303: F527-F539. doi: 10.1152/ajprenal.00134.2012.
50. Kimura T, Takahashi M, Yan K, Sakurai H,. Expression of SLC2A9 isoforms in the kidney and their localization in polarized epithelial cells. PLoS One 2014; 9: e84996. doi: 10.1371/journal.pone.0084996.
51. Gonzalez-Sicilia L, Garcia-Estan J, Martinez-Blazquez A, et al., Renal metabolism of uric acid in type I insulin-dependent diabetic patients: relation to metabolic compensation. Horm Metab Res 1997; 29: 520-523.
52. Bonsnes RW, Dana ES,. On the increased uric acid clearance following the intravenous infusion of hypertonic glucose solutions. J Clin Invest 1946; 25: 386-388.